Dysfunctional Dendritic Cells Limit Antigen-specific T Cell Response in Glioma

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2022 May 24

PMID 35609569

Authors

Mirco Friedrich

Markus Hahn

Julius Michel

Roman Sankowski

Michael Kilian

Niklas Kehl

Manina Gunter

Theresa Bunse

Stefan Pusch

Andreas von Deimling

Wolfgang Wick

Stella E Autenrieth

Marco Prinz

Michael Platten

Lukas Bunse

Affiliations

Soon will be listed here.

Abstract

Background: Dendritic cells (DC), the most potent professional antigen presenting cells capable of effective cross-presentation, have been demonstrated to license T helper cells to induce antitumor immunity in solid tumors. Specific DC subtypes are recruited to the injured brain by microglial chemokines, locally adapting to distinct transcriptional profiles. In isocitrate dehydrogenase (IDH) type 1 mutant gliomas, monocyte-derived macrophages have recently been shown to display an attenuated intratumoral antigen presentation capacity as consequence of the local accumulation of the oncometabolite R-2-hydroxyglutarate. The functionality and the contribution of DC to the IDH-mutant tumor microenvironment (TME) remains unclear.

Methods: Frequencies and intratumoral phenotypes of human DC in IDH-wildtype (IDHwt) and -mutant high-grade gliomas are comparatively assessed by transcriptomic and proteomic profiling. DC functionality is investigated in experimental murine glioblastomas expressing the model antigen ovalbumin. Single-cell sequencing-based pseudotime analyses and spectral flow cytometric analyses are used to profile DC states longitudinally.

Results: DC are present in primary and recurrent high-grade gliomas and interact with other immune cell types within the TME. In murine glioblastomas, we find an IDH-status-associated major histocompatibility class I-restricted cross-presentation of tumor antigens by DC specifically in the tumor but not in meninges or secondary lymphoid organs of tumor-bearing animals. In single-cell sequencing-based pseudotime and longitudinal spectral flow cytometric analyses, we demonstrate an IDH-status-dependent differential, exclusively microenvironmental education of DC.

Conclusions: Glioma-associated DCs are relevantly abundant in human IDHwt and mutant tumors. Glioma IDH mutations result in specifically educated, dysfunctional DCs via paracrine reprogramming of infiltrating monocytes, providing the basis for combinatorial immunotherapy concepts against IDH mutant gliomas.

Citing Articles

Deciphering mechanical cues in the microenvironment: from non-malignant settings to tumor progression.

Zhu Y, Chen J, Chen C, Tang R, Xu J, Shi S Biomark Res. 2025; 13(1):11.

PMID: 39849659 PMC: 11755887. DOI: 10.1186/s40364-025-00727-9.

Vagus nerve stimulation: Novel concept for the treatment of glioblastoma and solid cancers by cytokine (interleukin-6) reduction, attenuating the SASP, enhancing tumor immunity.

Brem S Brain Behav Immun Health. 2024; 42:100859.

PMID: 39512605 PMC: 11541944. DOI: 10.1016/j.bbih.2024.100859.

The challenges and clinical landscape of glioblastoma immunotherapy.

Ng A, Steve T, Jamouss K, Arham A, Kawtharani S, Assi H CNS Oncol. 2024; 13(1):2415878.

PMID: 39469854 PMC: 11524205. DOI: 10.1080/20450907.2024.2415878.

Co-culture models for investigating cellular crosstalk in the glioma microenvironment.

Niu X, Zhang Y, Wang Y Cancer Pathog Ther. 2024; 2(4):219-230.

PMID: 39371093 PMC: 11447344. DOI: 10.1016/j.cpt.2023.11.002.

Enhancing cancer immunotherapy: Nanotechnology-mediated immunotherapy overcoming immunosuppression.

Chen Y, Zhou Q, Jia Z, Cheng N, Zhang S, Chen W Acta Pharm Sin B. 2024; 14(9):3834-3854.

PMID: 39309502 PMC: 11413684. DOI: 10.1016/j.apsb.2024.05.032.

References

Luo X, Dalod M . The quest for faithful in vitro models of human dendritic cells types. Mol Immunol. 2020; 123:40-59. DOI: 10.1016/j.molimm.2020.04.018. View

Barry K, Hsu J, Broz M, Cueto F, Binnewies M, Combes A . A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018; 24(8):1178-1191. PMC: 6475503. DOI: 10.1038/s41591-018-0085-8. View

Friedrich M, Sankowski R, Bunse L, Kilian M, Green E, Ramallo Guevara C . Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. Nat Cancer. 2022; 2(7):723-740. DOI: 10.1038/s43018-021-00201-z. View

Klasen C, Ziehm T, Huber M, Asare Y, Kapurniotu A, Shachar I . LPS-mediated cell surface expression of CD74 promotes the proliferation of B cells in response to MIF. Cell Signal. 2018; 46:32-42. DOI: 10.1016/j.cellsig.2018.02.010. View

Villani A, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J . Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017; 356(6335). PMC: 5775029. DOI: 10.1126/science.aah4573. View

Friedrich M, Bunse L, Wick W, Platten M . Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas. Curr Opin Oncol. 2018; 30(6):368-374. DOI: 10.1097/CCO.0000000000000478. View

Boltjes A, van Wijk F . Human dendritic cell functional specialization in steady-state and inflammation. Front Immunol. 2014; 5:131. PMC: 3978316. DOI: 10.3389/fimmu.2014.00131. View

Segura E, Amigorena S . Inflammatory dendritic cells in mice and humans. Trends Immunol. 2013; 34(9):440-5. DOI: 10.1016/j.it.2013.06.001. View

Munn D, Mellor A . IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol. 2016; 37(3):193-207. PMC: 4916957. DOI: 10.1016/j.it.2016.01.002. View

10.

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

11.

Venteicher A, Tirosh I, Hebert C, Yizhak K, Neftel C, Filbin M . Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science. 2017; 355(6332). PMC: 5519096. DOI: 10.1126/science.aai8478. View

12.

Klasen C, Ohl K, Sternkopf M, Shachar I, Schmitz C, Heussen N . MIF promotes B cell chemotaxis through the receptors CXCR4 and CD74 and ZAP-70 signaling. J Immunol. 2014; 192(11):5273-84. DOI: 10.4049/jimmunol.1302209. View

13.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

14.

Bottcher C, Schlickeiser S, Sneeboer M, Kunkel D, Knop A, Paza E . Human microglia regional heterogeneity and phenotypes determined by multiplexed single-cell mass cytometry. Nat Neurosci. 2018; 22(1):78-90. DOI: 10.1038/s41593-018-0290-2. View

15.

Locarno C, Simonelli M, Carenza C, Capucetti A, Stanzani E, Lorenzi E . Role of myeloid cells in the immunosuppressive microenvironment in gliomas. Immunobiology. 2019; 225(1):151853. DOI: 10.1016/j.imbio.2019.10.002. View

16.

Menetrier-Caux C, Thomachot M, Alberti L, Montmain G, Blay J . IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Res. 2001; 61(7):3096-104. View

17.

Hu X, Deng Q, Ma L, Li Q, Chen Y, Liao Y . Meningeal lymphatic vessels regulate brain tumor drainage and immunity. Cell Res. 2020; 30(3):229-243. PMC: 7054407. DOI: 10.1038/s41422-020-0287-8. View

18.

Omuro A, DeAngelis L . Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013; 310(17):1842-50. DOI: 10.1001/jama.2013.280319. View

19.

Klemm F, Maas R, Bowman R, Kornete M, Soukup K, Nassiri S . Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells. Cell. 2020; 181(7):1643-1660.e17. PMC: 8558904. DOI: 10.1016/j.cell.2020.05.007. View

20.

Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M . Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat Med. 2018; 24(8):1192-1203. DOI: 10.1038/s41591-018-0095-6. View